Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | OXTR | P30559 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3948632 | 0.99 | HRH3 (0.47) | HRH3CHRNA7ACHECNR1 | |
| SCHEMBL3388045 | 0.95 | HRH3 (0.52) | HRH3CHRNA7CNR1CNR2OXTR | |
| SCHEMBL3387634 | 0.91 | HRH3 (0.44) | HRH3CHRNA7OXTR | |
| SCHEMBL3388925 | 0.89 | HRH3 (0.45) | HRH3CHRNA7OXTR | |
| SCHEMBL3387874 | 0.89 | HRH3 (0.44) | HRH3CHRNA7CNR1CNR2OXTR | |
| SCHEMBL3388747 | 0.87 | HRH3 (0.43) | HRH3CHRNA7CNR1CNR2OXTR | |
| SCHEMBL3385999 | 0.86 | HTR6 (0.52) | HRH3CHRNA7OXTR | |
| SCHEMBL3383957 | 0.86 | HRH3 (0.47) | HRH3CNR2 | |
| SCHEMBL3390210 | 0.85 | HRH3 (0.43) | HRH3CHRNA7CNR2OXTR | |
| SCHEMBL3390069 | 0.85 | HRH3 (0.50) | HRH3ACHEOXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101605757-A | Be used for (indoles-4-yl) of obesity treatment-or (indoles-5-yl)-piperazinyl methanone derivatives | HOFFMANN LA ROCHE (CH) | 2009-12-16 | — | — | CN | claimed |
| US-7557108-B2 | (Indol-4-yl) or (indol-5-yl)-piperazinylmethanones | HOFFMANN-LA ROCHE INC. (US) | 2009-07-07 | — | — | US | claimed |
| US-20080188486-A1 | (INDOL-4-YL) OR (INDOL-5-YL)-PIPERAZINYLMETHANONES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-07 | — | — | US | claimed |
| CN-101605757-A | Be used for (indoles-4-yl) of obesity treatment-or (indoles-5-yl)-piperazinyl methanone derivatives | HOFFMANN LA ROCHE (CH) | 2009-12-16 | — | — | CN | disclosed |
| US-7557108-B2 | (Indol-4-yl) or (indol-5-yl)-piperazinylmethanones | HOFFMANN-LA ROCHE INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-20080188486-A1 | (INDOL-4-YL) OR (INDOL-5-YL)-PIPERAZINYLMETHANONES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188486-A1 | (INDOL-4-YL) OR (INDOL-5-YL)-PIPERAZINYLMETHANONES | HRH4, HRH3, H1-3 | HRH3 2/4885CHRNA7 172/4885ACHE 1068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.